licensing@biovisionglobal.com

licensing@biovisionglobal.com

Bio-Manufacture Facility - Saudi Arabia

Founded in our mission to provide equitable access to biotherapeutics in the global south, Biovision and The Bio Investments Group has partnered with the Kingdom to build a state-of-the-art facility... 

Founded in our mission to provide equitable access to biotherapeutics in the global south, Biovision and The Bio Investments Group has partnered with the Kingdom to build a state-of-the-art facility... 

Project Name:

Bio-Manufacture Facility - Saudi Arabia

Description

The Bio Investments Group recently received state approval for a bio-manufacturing facility in Saudi Arabia. With an annual production capacity of 20 million to 30 million doses, this facility will be a hallmark example of the Kingdom's national strategy to produce treatments locally.

Industry:

Biotherapeutics

Release Date:

Est. Q1 2026

DIRECTIVE

The Bio Investments Group has given a directive to BioVision to acquire licenses to best in class biotherapeutics. We are comitted to providing the safest and most effective treatments by focusing solely on FDA and EMA approved therapeutic assets 

The Bio Investments Group has given a directive to BioVision to acquire licenses to best in class biotherapeutics. We are comitted to providing the safest and most effective treatments by focusing solely on FDA and EMA approved therapeutic assets 

DESIRED INDICATIONS

While we are interested in any areas where there is a regional need, we have a strong interest in biotherapeutics indicated in Oncology, Immunology, and Autoimmune Diseases, particularly those addressing critical unmet medical needs in emerging markets. 

While we are interested in any areas where there is a regional need, we have a strong interest in biotherapeutics indicated in Oncology, Immunology, and Autoimmune Diseases, particularly those addressing critical unmet medical needs in emerging markets. 

PROCESS

From identifying high-impact biologics to securing strategic partnerships, BioVision Global drives the seamless delivery of innovative treatments to underserved regions. 

From identifying high-impact biologics to securing strategic partnerships, BioVision Global drives the seamless delivery of innovative treatments to underserved regions. 

Our journey begins with a thorough assessment of market needs and healthcare gaps, particularly in indicated areas affecting sizeable populations. Using our extensive network and expertise, we pinpoint advanced biologics that align with the priorities of leading pharmaceutical innovators. Each potential asset undergoes detailed evaluation to ensure it not only meets critical unmet medical needs but also offers a strategic fit for regional markets. This data-driven approach enables us to target opportunities that maximize both patient impact and partner value.

After identifying high-value assets, we collaborate with our partners to craft licensing agreements tailored to regional needs, ensuring regulatory compliance and IP protection. By leveraging world-class manufacturing capabilities, such as our biologics hub in Saudi Arabia, we will localize production for cost-effective scalability. This integrated process accelerates market access for transformative treatments, delivering measurable benefits for patients, communities, and our partners alike.